An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib,...
Vous n'êtes pas connecté
THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy in stage III resected colon cancer, according to a study...
An analysis of data from a randomised clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib,...
MONDAY, June 24, 2024 -- For patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib is associated with a...
Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored...
Breast cancer is a complex disease with varying degrees of severity and treatment approaches. Central to understanding and managing breast cancer is...
Introducing a novel approach to enhance checkpoint inhibitor therapy for cancer, promising improved treatment outcomes and efficacy in clinical...
Study identifies a pivotal vascular growth factor crucial for advancing colon and renal cancer treatments, offering promising avenues for medical...
A new study published in JAMA Network Open by an international cohort of researchers provides the latest data on the effectiveness of treating...
An artificial intelligence-powered method for detecting tumour DNA in blood has shown unprecedented sensitivity in predicting cancer recurrence, in a...
Administering chemotherapy before surgery has shown benefits for select pancreatic cancer patients potentially improving treatment outcomes and...
FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free...